Pharming signs agreement with NewBridge Pharmaceuticals for the commercialization of RUCONEST® in the Middle East and North Africa

July 20, 2021 at 12:00 AM EDT
Supporting Materials:

Pharming Group announces it has entered into an exclusive licence agreement with NewBridge Pharmaceuticals (“NewBridge”) for the distribution of RUCONEST® (conestat alfa) in the Middle East and North Africa (“MENA”).